Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy. Read more about Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy.
Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. Read more about Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.
Chordoid glioma of the third ventricle: report of a rapidly progressive case. Read more about Chordoid glioma of the third ventricle: report of a rapidly progressive case.
Erratum to: The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. Read more about Erratum to: The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. Read more about Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Read more about Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. Read more about The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
Erratum to: Surgical resection of fourth ventricular ependymomas: case series and technical nuances. Read more about Erratum to: Surgical resection of fourth ventricular ependymomas: case series and technical nuances.
Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Read more about Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Read more about Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
